Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05246670 · ClinicalTrials.gov registry record · Phase 2
PEA for the Relief of Chemotherapy-Induced Peripheral Neuropathy
A Phase 2 study of Malignant Solid Neoplasm and Hematopoietic and Lymphoid Cell Neoplasm, sponsored by Academic and Community Cancer Research United.
- Active
- Registry status
- Phase 2
- Development phase
- 88
- Enrollment target
- 10
- Study locations
NCT05246670 is a Phase 2 study of Malignant Solid Neoplasm and Hematopoietic and Lymphoid Cell Neoplasm that is active but no longer recruiting, run by Academic and Community Cancer Research United. The registered enrollment target is 88 participants, below the 1,140-participant average among 176 other Malignant Solid Neoplasm trials with a reported enrollment target (92% lower). The trial reports 10 study locations across 9 states.
The verdict
NCT05246670, a Phase 2 study of Malignant Solid Neoplasm and Hematopoietic and Lymphoid Cell Neoplasm, is active but no longer recruiting, sponsored by Academic and Community Cancer Research United.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 88 participants
- Enrollment target
- 10
- Study locations
Study Summary
This phase II trial tests whether PEA works to relieve the symptoms of chemotherapy-induced peripheral neuropathy in patients with cancer. Chemotherapy-induced peripheral neuropathy refers to a nerve problem that causes pain, numbness, tingling, or muscle weakness in different parts of the body, and is caused by chemotherapy. PEA may be useful against bothersome nerve symptoms.
Conditions Studied
Interventions
- OTHER Quality-of-Life Assessment
- DRUG Placebo Administration
- DRUG Palmidrol
Study Locations (10)
Wisconsin
- Mayo Clinic Health System Eau Claire Hospital-Luther Campus - Eau Claire
- Mayo Clinic Health System-Franciscan Healthcare - La Crosse
Connecticut
- Middlesex Hospital - Middletown
Illinois
- Carle Cancer Center NCI Community Oncology Research Program - Urbana
Iowa
- Siouxland Regional Cancer Center - Sioux City
Minnesota
- Mayo Clinic - Rochester
North Carolina
- Cone Health Cancer Center - Greensboro
Pennsylvania
- Geisinger Medical Center - Danville
South Dakota
- Rapid City Regional Hospital - Rapid City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2022-05-16 |
| Est. Completion | 2026-02-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05246670
The ClinicalTrials.gov registry entry for NCT05246670 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 88 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,140-participant average among 176 other Malignant Solid Neoplasm trials with a reported enrollment target (92% lower). The listed sponsor is Academic and Community Cancer Research United, which has 42 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Malignant Solid Neoplasm appearing as the primary indexed condition, and to 3 interventions - of which Quality-of-Life Assessment is the first listed.
NCT05246670 reports 10 study locations spanning 9 distinct geographic areas - top geographies include Wisconsin, Connecticut, Illinois.
Frequently Asked Questions
What is clinical trial NCT05246670 about?
NCT05246670 is a clinical study titled "PEA for the Relief of Chemotherapy-Induced Peripheral Neuropathy". This phase II trial tests whether PEA works to relieve the symptoms of chemotherapy-induced peripheral neuropathy in patients with cancer. Chemotherapy-induced peripheral neuropathy refers to a nerve problem that causes pain, numbness, tingling, or muscle weakness in different parts of the body, and...
What is the current status of trial NCT05246670?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 88 participants. The study started on 2022-05-16. Estimated completion is 2026-02-28.
What conditions does trial NCT05246670 study?
This clinical trial studies the following conditions: Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Chemotherapy-induced Peripheral Neuropathy.
What interventions are being tested in trial NCT05246670?
The interventions under investigation include: Quality-of-Life Assessment (OTHER), Placebo Administration (DRUG), Palmidrol (DRUG).
Who is sponsoring clinical trial NCT05246670?
This trial is sponsored by Academic and Community Cancer Research United, which has 42 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05246670 being conducted?
This trial has 10 study locations across Connecticut, Illinois, Iowa, Minnesota, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignant Solid Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Culturally-Tailored Mobile Health and Social Media Physical Activity Intervention for Improving Physical Activity in Hispanic or Latino/Latina Adolescent and Young Adult Childhood Cancer Survivors, Walking Juntos Study
RECRUITING · Phase 2
-
Duloxetine and Neurofeedback Training for the Treatment of Chemotherapy Induced Peripheral Neuropathy
RECRUITING · Phase 2
-
Cryocompression With or Without Cilostazol for the Prevention of Paclitaxel-induced Neuropathy in Patients With Gynecological Cancers
RECRUITING · Phase 2
-
Time-Restricted Eating Versus Nutritional Counseling for the Reduction of Radiation or Chemoradiation Tx Side Effects in Patients With Prostate, Cervical, or Rectal Cancers
RECRUITING · Phase 2
-
Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)
RECRUITING · Phase 2
-
Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas
RECRUITING · Phase 2
Explore more on PlainTrial
Malignant Solid Neoplasm
All registered trials for this condition
Hematopoietic and Lymphoid Cell Neoplasm
All registered trials for this condition
Connecticut
All trials with a study site in Connecticut
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.